作者
Craig J Smith, Sharon Hulme, Andy Vail, Calvin Heal, Adrian R Parry-Jones, Sylvia Scarth, Karen Hopkins, Margaret Hoadley, Stuart M Allan, Nancy J Rothwell, Stephen J Hopkins, Pippa J Tyrrell
发表日期
2018/5
期刊
Stroke
卷号
49
期号
5
页码范围
1210-1216
出版商
Lippincott Williams & Wilkins
简介
Background and Purpose
The proinflammatory cytokine IL-1 (interleukin-1) has a deleterious role in cerebral ischemia, which is attenuated by IL-1 receptor antagonist (IL-1Ra). IL-1 induces peripheral inflammatory mediators, such as interleukin-6, which are associated with worse prognosis after ischemic stroke. We investigated whether subcutaneous IL-1Ra reduces the peripheral inflammatory response in acute ischemic stroke.
Methods
SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke) was a single-center, double-blind, randomized, placebo-controlled phase 2 trial of subcutaneous IL-1Ra (100 mg administered twice daily for 3 days) in patients presenting within 5 hours of ischemic stroke onset. Randomization was stratified for baseline National Institutes of Health Stroke Scale score and thrombolysis. Measurement of plasma interleukin-6 and other peripheral inflammatory …
学术搜索中的文章
CJ Smith, S Hulme, A Vail, C Heal, AR Parry-Jones… - Stroke, 2018